These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD. Med Lett Drugs Ther; 2014 Apr; 56(1440):30-1. PubMed ID: 24736248 [No Abstract] [Full Text] [Related]
9. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969 [TBL] [Abstract][Full Text] [Related]
10. Fluticasone-vilanterol combination approved for COPD. Traynor K Am J Health Syst Pharm; 2013 Jun; 70(12):1008. PubMed ID: 23719869 [No Abstract] [Full Text] [Related]
11. ▼Relvar Ellipta for COPD. Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005 [TBL] [Abstract][Full Text] [Related]
12. Chronic Obstructive Pulmonary Disease: When Pulmonologists Do Something Good for the Heart. Watz H Am J Respir Crit Care Med; 2016 Apr; 193(7):703-4. PubMed ID: 27035775 [No Abstract] [Full Text] [Related]
13. Relvar Ellipta for asthma. Drug Ther Bull; 2014 Aug; 52(8):93-6. PubMed ID: 25125553 [TBL] [Abstract][Full Text] [Related]
14. Response to Letter to the Editor: Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Donohue JF Respir Med; 2016 Jan; 110():81. PubMed ID: 26689766 [No Abstract] [Full Text] [Related]
15. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Matera MG; Capuano A; Cazzola M Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512 [TBL] [Abstract][Full Text] [Related]
16. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Banerji D; Patalano F Respir Med; 2016 Jan; 110():79-80. PubMed ID: 26211886 [No Abstract] [Full Text] [Related]
17. Could Pharmacologic Lung Deflation Modify Cardiac Structural and Functional Alterations? Savas G; Kalay N; Gulmez I Am J Respir Crit Care Med; 2016 Apr; 193(8):932. PubMed ID: 27082537 [No Abstract] [Full Text] [Related]
18. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028 [TBL] [Abstract][Full Text] [Related]
19. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127 [TBL] [Abstract][Full Text] [Related]
20. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease. Bakerly ND; Woodcock A; New JP; Gibson JM; Wu W; Leather D; Vestbo J Respir Res; 2015 Sep; 16(1):101. PubMed ID: 26337978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]